Gyre Therapeutics, Inc. (GYRE) stock
Close on Nov 17, 2026Market cap $508.49MP/E –Yield –
Gyre Therapeutics, Inc. saw revenue fall 3.7% to $108.15M over the twelve months to Sep 30, 2026. Operating income fell 809.3% to -$15.55M, moving the operating margin from 2.0% to -14.4%. Free cash flow was -$7.75M. At the latest close the market valued the company at $508.49M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $508.49M
- P/E ratio
- –
- Price to sales
- 4.70
- Price to book
- 4.71
- Dividend yield
- –
- Free cash flow yield
- -1.52%
Fundamentals
- Revenue
- $108.15M
- Net income
- -$36.65M
- EPS, diluted
- -$0.23
- Free cash flow
- -$7.75M
- Book value per share
- $1.02
- Diluted shares
- 106M
Trading
- Next earnings
- Mar 11, 2027 (estimated, after the close)
- Previous close
- $4.39
- Open
- $4.39
- Day's range
- $4.32 – $4.60
- Volume
- 215,957
- Average volume (20 days)
- 226,525
- Index membership
- Russell 2000 (since Sep 2024)
- 52-week range
- $3.97 – $9.14
- RSI (14 days)
- 39.8
- Volatility (1 year)
- 67.0%
- Relative volume
- 1.61×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | GYRE | S&P 500 | Difference | GYRE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.0% | -4.0% | −21.0 pts | ||
| 3 months | -33.0% | -5.0% | −28.1 pts | ||
| Year to date | -35.4% | +8.2% | −43.7 pts | ||
| 1 year | -43.1% | +11.2% | −54.4 pts | ||
| 3 years | -69.0% | +68.5% | −137.5 pts | -32.3% | +19.0% |
| 5 years | -65.9% | +67.3% | −133.2 pts | -19.4% | +10.8% |
| 10 years | -95.5% | +291.6% | −387.1 pts | -26.6% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Gyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
About Gyre Therapeutics
Pharmaceutical Preparations
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies targeting organ fibrosis and inflammatory conditions. The company's commercial portfolio includes ETUARY (pirfenidone) and Etorel (nintedanib) for idiopathic pulmonary fibrosis and other interstitial lung disorders, as well as Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its clinical pipeline features Hydronidone for liver fibrosis, along with candidates addressing acute liver failure, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. Gyre supplies therapies to adult patients requiring specialized pulmonary, hepatologic, and hospital-based medical care.
Company profile, executives and historyGyre Therapeutics stock: common questions
What is Gyre Therapeutics's stock price?
GYRE closed at $4.56 on Nov 17, 2026, up 3.87% on the day. Over the past 52 weeks it traded between $3.97 and $9.14.
What is Gyre Therapeutics's market cap?
Gyre Therapeutics was worth $508.49M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is GYRE's P/E ratio?
Gyre Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.23), so it has no meaningful P/E ratio.
How much revenue does Gyre Therapeutics make?
Gyre Therapeutics reported revenue of $108.15M for the twelve months to Sep 30, 2026, down 3.7% from a year earlier.
Does Gyre Therapeutics pay a dividend?
No. Gyre Therapeutics has not paid a cash dividend over the last twelve months.
When does Gyre Therapeutics report earnings next?
Gyre Therapeutics is expected to report Q4 FY2026 results on Mar 11, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has GYRE stock performed over the past year?
Including dividends, GYRE returned -43.1% over the past year, against +11.2% for the S&P 500.
How many GYRE shares are sold short?
2M shares were sold short at the latest FINRA report, 32.40% of the float, or 14.2 days of average trading volume.
Who are Gyre Therapeutics's competitors?
Companies most similar to Gyre Therapeutics by business, industry and size include GOSS, CYTK, ZVRA, RCUS, ETON.
See a number that looks wrong?